| Hazard Information | Back Directory | [Uses]
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer[1]. | [in vivo]
Izalontamab (5-46 mg/kg; i.v., every 7 days once, 4 doses in total) shows different anti-tumor efficacy in different types of tumors[1]. | Animal Model: | Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts[1] | | Dosage: | 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150) | | Administration: | Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total | | Result: | Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.
|
| [References]
[1] Xue J, et al. Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. J Pharm Sci. 2020 Oct;109(10):3172-3180. DOI:10.1016/j.xphs.2020.06.015 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|